loading
Precedente Chiudi:
$7.96
Aprire:
$7.98
Volume 24 ore:
86,535
Relative Volume:
0.05
Capitalizzazione di mercato:
$2.51B
Reddito:
$2.68B
Utile/perdita netta:
$-184.45M
Rapporto P/E:
-11.78
EPS:
-0.6805
Flusso di cassa netto:
$229.23M
1 W Prestazione:
-2.92%
1M Prestazione:
+1.31%
6M Prestazione:
-8.98%
1 anno Prestazione:
+7.92%
Intervallo 1D:
Value
$7.93
$8.045
Intervallo di 1 settimana:
Value
$7.79
$8.305
Portata 52W:
Value
$6.50
$9.475

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Name
Nome
Amneal Pharmaceuticals Inc
Name
Telefono
908-947-3120
Name
Indirizzo
400 Crossing Boulevard, 3rd Floor, Bridgewater
Name
Dipendente
5,210
Name
Cinguettio
@amnealpharma
Name
Prossima data di guadagno
2025-05-02
Name
Ultimi documenti SEC
Name
AMRX's Discussions on Twitter

Confronta AMRX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
AMRX
Amneal Pharmaceuticals Inc
8.02 2.59B 2.68B -184.45M 229.23M -0.6805
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
152.09 68.05B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.72 46.58B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.745 43.71B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.59 18.40B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
302.44 13.23B 2.99B 1.21B 1.13B 25.06

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-06-06 Iniziato Goldman Buy
2025-02-24 Aggiornamento JP Morgan Neutral → Overweight
2024-09-06 Aggiornamento JP Morgan Underweight → Neutral
2021-04-07 Ripresa RBC Capital Mkts Sector Perform
2021-03-08 Aggiornamento Goldman Sell → Buy
2020-12-14 Aggiornamento Barclays Equal Weight → Overweight
2020-12-14 Aggiornamento Guggenheim Neutral → Buy
2020-07-27 Iniziato Goldman Sell
2020-05-12 Aggiornamento Guggenheim Sell → Neutral
2019-12-12 Downgrade Raymond James Outperform → Mkt Perform
2019-11-12 Downgrade JP Morgan Neutral → Underweight
2019-11-07 Downgrade SVB Leerink Outperform → Mkt Perform
2019-07-22 Aggiornamento SVB Leerink Mkt Perform → Outperform
2019-07-11 Downgrade RBC Capital Mkts Outperform → Sector Perform
2019-07-08 Aggiornamento Piper Jaffray Neutral → Overweight
2019-06-11 Iniziato Barclays Equal Weight
2019-05-21 Aggiornamento Raymond James Mkt Perform → Strong Buy
2019-03-20 Iniziato SunTrust Buy
2019-03-08 Downgrade SVB Leerink Outperform → Mkt Perform
2018-12-14 Downgrade Morgan Stanley Overweight → Equal-Weight
2018-10-16 Downgrade SunTrust Buy → Hold
2018-08-13 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2018-07-23 Iniziato Morgan Stanley Overweight
2018-06-22 Iniziato B. Riley FBR, Inc. Buy
Mostra tutto

Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie

pulisher
03:43 AM

What analysts say about Amneal Pharmaceuticals Inc. stockSignificant capital appreciation - Autocar Professional

03:43 AM
pulisher
02:57 AM

What drives Amneal Pharmaceuticals Inc. stock priceGame-changing capital returns - Autocar Professional

02:57 AM
pulisher
Jul 22, 2025

Amneal Pharmaceuticals Inc. Stock Analysis and ForecastHigh-return market picks - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Amneal Pharmaceuticals Inc. a good long term investmentFree Stock Selection - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Amneal Announces Proposed Refinancing of Existing Credit - GlobeNewswire

Jul 22, 2025
pulisher
Jul 21, 2025

Amneal reports 3% revenue growth in Q2, advances deleveraging - Investing.com India

Jul 21, 2025
pulisher
Jul 21, 2025

Amneal (AMRX) targets $2.55B debt refinancing via loans & notes | AMRX SEC FilingForm 8-K - Stock Titan

Jul 21, 2025
pulisher
Jul 21, 2025

Amneal Pharmaceuticals Reports Preliminary Q2 2025 Financial Results Indicating Growth and Deleveraging Efforts - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 21, 2025

Amneal Pharmaceuticals Unveils Massive $2.55 Billion Debt Restructuring PlanWhat's Changing - Stock Titan

Jul 21, 2025
pulisher
Jul 18, 2025

Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada - The Manila Times

Jul 18, 2025
pulisher
Jul 18, 2025

Thérapeutique Knight annonce le dépôt d’une nouvelle soumission réglementaire pour CREXONT® (carbidopa et lévodopa) au Canada en capsules à libération prolongée - GlobeNewswire Inc.

Jul 18, 2025
pulisher
Jul 16, 2025

Parkinson's Disease Pipeline 2025: MOA and ROA Insights, - openPR.com

Jul 16, 2025
pulisher
Jul 13, 2025

Amneal Pharmaceuticals (AMRX) Announces FDA Approval of Prednisolone Acetate Ophthalmic Suspension - MSN

Jul 13, 2025
pulisher
Jul 10, 2025

Amneal to Report Second Quarter 2025 Results on August 5, 2025 - GlobeNewswire

Jul 10, 2025
pulisher
Jul 09, 2025

Amneal Earnings: How to Join Q2 2025 Results Call on August 5 - Stock Titan

Jul 09, 2025
pulisher
Jul 04, 2025

Riot Platforms selling more Bitfarms (BITF) - The Globe and Mail

Jul 04, 2025
pulisher
Jul 02, 2025

Analysts Bullish as Amneal Pharmaceuticals, Inc. (AMRX) Director Sells Over 94K Shares - Yahoo Finance

Jul 02, 2025
pulisher
Jun 30, 2025

Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year? - Yahoo Finance

Jun 30, 2025
pulisher
Jun 27, 2025

Kashiv’s Xolair Biosimilar Nears US And EU Filings As Phase III Data Reports - insights.citeline.com

Jun 27, 2025
pulisher
Jun 26, 2025

5 Revealing Analyst Questions From Amneal’s Q1 Earnings Call - FinancialContent

Jun 26, 2025
pulisher
Jun 25, 2025

Amneal reports positive phase 3 results for XOLAIR biosimilar By Investing.com - Investing.com Nigeria

Jun 25, 2025
pulisher
Jun 24, 2025

Amneal Pharmaceuticals Breaks Above 200-Day Moving AverageBullish for AMRX - Nasdaq

Jun 24, 2025
pulisher
Jun 19, 2025

Investing in Amneal Pharmaceuticals (NASDAQ:AMRX) three years ago would have delivered you a 157% gain - simplywall.st

Jun 19, 2025
pulisher
Jun 18, 2025

Insider Sell: Gautam Patel Sells 94,906 Shares of Amneal Pharmac - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Insider Sell: Gautam Patel Sells 94,906 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Parkinson’s Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | AbbVie, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevance, Amneal Pharma, Pharma Two B, Jazz Pharma - Barchart.com

Jun 17, 2025
pulisher
Jun 17, 2025

Parkinson's Disease Market to Show Remarkable Growth Trends - openPR.com

Jun 17, 2025
pulisher
Jun 13, 2025

Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? - Yahoo Finance

Jun 13, 2025
pulisher
Jun 13, 2025

Epinephrine Autoinjector Market Size, Share, and Competitive - openPR.com

Jun 13, 2025
pulisher
Jun 13, 2025

FDA approves Amneal’s prednisolone acetate eye drops, launch set for Q3 - Investing.com India

Jun 13, 2025
pulisher
Jun 13, 2025

FDA approves Amneal's prednisolone acetate ophthalmic suspension - Eyes On Eyecare

Jun 13, 2025
pulisher
Jun 12, 2025

Insider Sell: Gautam Patel Sells 56,426 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Amneal Pharmaceuticals receives U.S. FDA approval for prednisolone acetate - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension - MarketScreener

Jun 12, 2025
pulisher
Jun 12, 2025

Amneal Pharmaceuticals (AMRX) Gains FDA Approval for Eye Drug | AMRX Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

FDA Green Lights Amneal's $201M Generic Eye Drug: Q3 2025 Launch Set for Pred Forte Alternative - Stock Titan

Jun 12, 2025
pulisher
Jun 11, 2025

Amneal Recalls Oral Antibiotic Over Contamination Issue - Infectious Disease Advisor

Jun 11, 2025
pulisher
Jun 10, 2025

Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Amneal Pharmaceuticals at Goldman Sachs Conference: Strategic Growth Vision By Investing.com - Investing.com Canada

Jun 10, 2025

Amneal Pharmaceuticals Inc Azioni (AMRX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$72.52
price up icon 0.26%
$15.14
price up icon 1.44%
$9.37
price up icon 1.46%
drug_manufacturers_specialty_generic RDY
$14.76
price up icon 2.39%
$133.50
price up icon 0.60%
$302.44
price up icon 1.71%
Capitalizzazione:     |  Volume (24 ore):